Q3 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
LeqvioⓇ adoption continues to expand steadily
Sales evolution
USD m
Ex-US
US
=
64
78
34
==
90
90
35
35
US: Building foundation for acceleration
Adoption
■
3,100 facilities have ordered Leqvio® (+16% vs. Q2)
■ >55% of business is from buy and bill
Enablers for future growth
■ Drive depth in key accounts with high utilization
■ Increase confidence in buy and bill
27
42
34
17
22
22
13
55
44
37
12
25
21
10
Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023
B&B Buy and Bill.
Pharmaceuticals, Inc.
■
Improve HCP targeting
Ex-US rollout continues
Approved in China and Japan
GROWTH
LEQVIO®
LeqvioⓇ is administered initially, again at 3 months, and then once every 6 months. Novartis has obtained global rights to develop, manufacture and commercialize LeqvioⓇ under a license agreement with Alnylam
14 Investor Relations | Q3 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation